Trials / Completed
CompletedNCT04201418
A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of Hereditary Transthyretin-Mediated (ATTRv) Amyloidosis With a V122I or T60A Mutation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 67 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effectiveness of patisiran in patients with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Patisiran | Patisiran-lipid complex injection, for intravenous use |
Timeline
- Start date
- 2019-12-18
- Primary completion
- 2022-05-24
- Completion
- 2022-05-24
- First posted
- 2019-12-17
- Last updated
- 2022-06-06
Locations
27 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04201418. Inclusion in this directory is not an endorsement.